United Therapeutics Co. (NASDAQ: UTHR – Get Rating) ‘s share price was down 3.1% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $ 224.15 and last traded at $ 224.15. Approximately 401 shares traded hands during trading, a decline of 100% from the average daily volume of 571,206 shares. The stock had previously closed at $ 231.29.
Specifically, CEO Martine A. Rothblatt sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $ 231.27, for a total value of $ 693,810.00. Following the transaction, the chief executive officer now owns 130 shares of the company stock, valued at $ 30,065.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, April 7th. The stock was sold at an average price of $ 185.52, for a total value of $ 1,113,120.00. Following the completion of the transaction, the executive vice president now directly owns 36,487 shares in the company, valued at approximately $ 6,769,068.24. The disclosure for this sale can be found here. In the last three months, insiders sold 47,000 shares of company stock worth $ 9,390,830. 12.10% of the stock is owned by corporate insiders.
UTHR has been the topic of several recent research reports. BTIG Research initiated coverage on United Therapeutics in a research note on Friday, February 11th. They issued a “neutral” rating on the stock. Wedbush increased their target price on United Therapeutics from $ 236.00 to $ 263.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 24th. Oppenheimer increased their target price on United Therapeutics from $ 275.00 to $ 300.00 in a research report on Thursday, May 5th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $ 225.00 to $ 238.00 in a research report on Tuesday, May 24th. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 1st. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $ 236.78.
The firm has a market cap of $ 10.34 billion, a PE ratio of 15.79, a PEG ratio of 5.10 and a beta of 0.61. The firm has a fifty day simple moving average of $ 191.61 and a two-hundred day simple moving average of $ 193.68. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.54 and a current ratio of 8.84.
United Therapeutics (NASDAQ: UTHR – Get Rating) last released its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported $ 5.03 earnings per share for the quarter, beating the consensus estimate of $ 2.96 by $ 2.07. The business had revenue of $ 461.90 million during the quarter, compared to analysts’ expectations of $ 420.02 million. United Therapeutics had a return on equity of 17.62% and a net margin of 38.87%. The firm’s revenue for the quarter was up 21.8% compared to the same quarter last year. During the same quarter last year, the business posted $ 0.61 EPS. Equities analysts forecast that United Therapeutics Co. will post 17.23 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of UTHR. Amundi Pioneer Asset Management Inc. lifted its stake in shares of United Therapeutics by 18.8% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company stock valued at $ 8,945,000 after purchasing an additional 12,087 shares during the last quarter. Morgan Stanley lifted its stake in shares of United Therapeutics by 245.3% in the 2nd quarter. Morgan Stanley now owns 129,990 shares of the biotechnology company stock valued at $ 23,323,000 after purchasing an additional 92,346 shares during the last quarter. US Bancorp DE lifted its stake in shares of United Therapeutics by 15.7% in the 3rd quarter. US Bancorp DE now owns 2,341 shares of the biotechnology company stock valued at $ 433,000 after purchasing an additional 317 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in shares of United Therapeutics by 10.4% in the 3rd quarter. First Republic Investment Management Inc. now owns 1,422 shares of the biotechnology company stock valued at $ 262,000 after purchasing an additional 134 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of United Therapeutics by 23.4% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 3,530 shares of the biotechnology company stock worth $ 652,000 after acquiring an additional 670 shares during the last quarter. 94.68% of the stock is owned by institutional investors and hedge funds.
About United Therapeutics: (NASDAQ: UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance exercise ability in PAH patients.
See Also:
Receive News & Ratings for United Therapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for United Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
.